지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.1
- 수록면
- 112 - 122 (11page)
- DOI
- 10.4143/crt.2022.381
이용수
초록· 키워드
오류제보하기
Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor receptor (<i>EGFR</i>) T790M mutation–positive non–small cell lung cancer, real-world evidence on the efficacy of osimertinib is not enough to reflect the complexity of the entire course of treatment. Herein, we report on the use of osimertinib in patients with <i>EGFR</i> T790M mutation–positive non–small cell lung cancer who had previously received EGFR tyrosine kinase inhibitor (TKI) treatment in Korea.Materials and Methods Patients with confirmed <i>EGFR</i> T790M after disease progression of prior EGFR-TKI were enrolled and administered osimertinib 80 mg daily. The primary effectiveness outcome was progression-free survival, with time-to-treatment discontinuation, treatment and adverse effects leading to treatment discontinuation, and overall survival being the secondary endpoints.Results A total of 558 individuals were enrolled, and 55.2% had investigator-assessed responses. The median progression-free survival was 14.2 months (95% confidence interval [CI], 13.0 to 16.4), and the median time-to-treatment discontinuation was 15.0 months (95% CI, 14.1 to 15.9). The median overall survival was 36.7 months (95% CI, 30.9 to not reached). The benefit with osimertinib was consistent regardless of the age, sex, smoking history, and primary <i>EGFR</i> mutation subtype. However, hepatic metastases at the time of diagnosis, the presence of plasma <i>EGFR</i> T790M, and the shorter duration of prior EGFR-TKI treatment were poor predictors of osimertinib treatment. Ten patients (1.8%), including three with pneumonitis, had to discontinue osimertinib due to severe adverse effects.Conclusion Osimertinib demonstrated its clinical effectiveness and survival benefit for <i>EGFR</i> T790M mutation–positive in Korean patients with no new safety signals.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
Cancer Research and Treatment
2022 .10
-
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Cancer Research and Treatment
2020 .01
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
A Phase II Trial of Osimertinib as the First-Line Treatment of Non-small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cancer Research and Treatment
2021 .01
-
Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014
Cancer Research and Treatment
2019 .01
-
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
Cancer Research and Treatment
2019 .01
-
Frequency of EGFR Mutations in Non-small Cell Lung Cancer Patients: Screening Data from West Siberia
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Double primary lung adenocarcinoma diagnosed by epidermal growth factor receptor mutation status
영남의대학술지
2017 .01
-
Double primary lung adenocarcinoma diagnosed by epidermal growth factor receptor mutation status
Journal of Yeungnam Medical Science
2017 .01
-
Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure
대한직업환경의학회지
2016 .03
-
Animal models and therapeutic molecular targets of lung cancer
한국실험동물학회 학술발표대회 논문집
2019 .01
-
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Journal of Pathology and Translational Medicine
2016 .01
-
Epidemiology of Lung Cancer in Korea: Recent Trends
Tuberculosis and Respiratory Diseases
2016 .01
-
EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Journal of Pathology and Translational Medicine
2019 .01
-
Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
Yonsei Medical Journal
2019 .01
-
Gefitinib에 내성을 보인 폐선암에서 발견된Epidermal Growth Factor Receptor 돌연변이 양성인 소세포폐암
대한내과학회지
2015 .01
-
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis
Cancer Research and Treatment
2023 .04
-
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer
Cancer Research and Treatment
2024 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0